Stem cell bioprocessing for regenerative medicine

Journal of Chemical Technology and Biotechnology

Volumn 89, Issue 1, 2014, Pages 34-47

  Fernandes, Tiago G ^a   Rodrigues, Carlos A V ^a   Diogo, Maria Margarida ^a   Cabral, Joaquim M S ^a  

^a Instituto de Biotecnologia e Bioengenharia Lisboa   (Portugal)

Author keywords

Bioprocessing; Regenerative medicine; Stem cells

Indexed keywords

NEURODEGENERATIVE DISEASES; REGULATORY COMPLIANCE;

BIOPROCESSING; CLINICAL APPLICATION; CONTROLLED CONDITIONS; ECONOMIC ADVANTAGES; HUNTINGTON'S DISEASE; NEUROLOGICAL DISORDERS; REGENERATIVE MEDICINE; STEM CELL TECHNOLOGY;

STEM CELLS;

ANTIBODY AFFINITY; AUTOMATION; BIOREACTOR; CELL AGGREGATION; CELL ENGINEERING; CELL REGENERATION; CELL SEPARATION; CELL TYPE; CLINICAL TRIAL (TOPIC); CRYOPRESERVATION; DEGENERATIVE DISEASE; EMBRYONIC STEM CELL; HUMAN; MICROCARRIER CULTURE; NONHUMAN; PLURIPOTENT STEM CELL; PURIFICATION; QUALITY CONTROL; REGENERATIVE MEDICINE; REVIEW; STEM CELL; STEM CELL CULTURE; STEM CELL NICHE;

EID: 84897050716     PISSN: 02682575     EISSN: 10974660     Source Type: Journal    
DOI: 10.1002/jctb.4189     Document Type: Review

References (141)

1. Nichols J and Smith A, Pluripotency in the embryo and in culture. Cold Spring Harb Perspect Biol 4:a008128 (2012).
2. Klimanskaya I, Rosenthal N and Lanza R, Derive and conquer: sourcing and differentiating stem cells for therapeutic applications. Nat Rev Drug Discov 7:131-142 (2008).
3. Pouton CW and Haynes JM, Pharmaceutical applications of embryonic stem cells. Adv Drug Deliv Rev 57:1918-1934 (2005).
4. Daley GQ, Stem cells: roadmap to the clinic. J Clin Invest 120:8-10 (2010).
5. Cohen DE and Melton D, Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet 12:243-252 (2011).
6. Discher DE, Mooney DJ and Zandstra PW, Growth factors, matrices, and forces combine and control stem cells. Science 324:1673-1677 (2009).
7. Placzek MR, Chung IM, Macedo HM, Ismail S, Mortera Blanco T, Lim M, Cha JM, Fauzi I, Kang Y, Yeo DC, Ma CY, Polak JM, Panoskaltsis N and Mantalaris A, Stem cell bioprocessing: fundamentals and principles. J R Soc Interface 6:209-232 (2009).
8. Polak JM and Mantalaris S, Stem cells bioprocessing: an important milestone to move regenerative medicine research into the clinical arena. Pediatr Res 63:461-466 (2008).
9. Ratcliffe E, Thomas RJ and Williams DJ, Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine. Br Med Bull 100:137-155 (2011).
10. Gobaa S, Hoehnel S, Roccio M, Negro A, Kobel S and Lutolf M, Artificial niche microarrays for probing single stem cell fate in high throughput. Nat Methods 8:949-955 (2011).
11. Kobel S and Lutolf M, High-throughput methods to define complex stem cell niches. Bio Techniques 48:ix-xxii (2010).
12. Peerani R, Onishi K, Mahdavi A, Kumacheva E and Zandstra P, Manipulation of signaling thresholds in 'engineered stem cell niches' identifies design criteria for pluripotent stem cell screens. PLoS One 4 (2009).
13. Vunjak-Novakovic G and Scadden DT, Biomimetic platforms for human stem cell research. Cell Stem Cell 8:252-261 (2011).
14. Fernandes TG, Diogo MM, Clark DS, Dordick JS and Cabral JMS, High-throughput cellular microarray platforms:applications in drug discovery, toxicology and stem cell research. Trends Biotechnol 27:342-349 (2009).
15. Peerani R and Zandstra PW, Enabling stem cell therapies through synthetic stem cell-niche engineering. J Clin Invest 120:60-70 (2010).
16. Ashton R, Keung A, Peltier J and Schaffer D, Progress and prospects for stem cell engineering. Annu Rev Chem Biomol Eng 2:479-502 (2011).
17. Kirouac DC and Zandstra PW, The systematic production of cells for cell therapies. Cell Stem Cell 3:369-381 (2008).
18. Ahrlund-Richter L, De Luca M, Marshak DR, Munsie M, Veiga A and Rao M, Isolation and production of cells suitable for human therapy:challenges ahead. Cell Stem Cell 4:20-26 (2009).
19. Newman RE, Yoo D, LeRoux MA and Danilkovitch-Miagkova A, Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 8:110-123 (2009).
20. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R and Uberti J, Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15:804-811 (2009).
21. Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA and Schatz DA, Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 36:710-715 (2008).
22. Harris DT, Badowski M, Ahmad N and Gaballa MA, The potential of cord blood stem cells for use in regenerative medicine. Expert Opin Biol Ther 7:1311-1322 (2007).
23. Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I and Lanza R, Embryonic stem cell trials for macular degeneration:a preliminary report. Lancet 379:713-720 (2012).
24. Lu B, Malcuit C, Wang S, Girman S, Francis P, Lemieux L, Lanza R and Lund R, Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 27:2126-2135 (2009).
25. Strauss S, Geron trial resumes, but standards for stem cell trials remain elusive. Nat Biotechnol 28:989-990 (2010).
26. Rathore AS, Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 27:546-553 (2009).
27. Lunyak VV and Rosenfeld MG, Epigenetic regulation of stem cell fate. Hum Mol Genet 17:R28-36 (2008).
28. Passier R and Mummery C, Origin and use of embryonic and adult stem cells in differentiation and tissue repair. Cardiovasc Res 58:324-335 (2003).
29. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S, Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872 (2007).
30. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein B and Jaenisch R, In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:318-324 (2007).
31. Yamanaka S, A fresh look at iPS cells. Cell 137:13-17 (2009).
32. Stadtfeld M and Hochedlinger K, Induced pluripotency: history, mechanisms, and applications. Genes Dev 24:2239-2263 (2010).
33. Knoepfler PS, Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 27:1050-1056 (2009).
34. Taylor CJ, Bolton EM and Bradley JA, Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci 366:2312-2322 (2011).
35. Czyz J, Wiese C, Rolletschek A, Blyszczuk P, Cross M and Wobus AM, Potential of embryonic and adult stem cells in vitro. Biol Chem 384:1391-1409 (2003).
36. Young H, Duplaa C, Romero-Ramos M, Chesselet M, Vourc'h P, Yost M, Ericson K, Terracio L, Asahara T, Masuda H, Tamura-Ninomiya S, Detmer K, Bray R, Steele T, Hixson D, el-Kalay M, Tobin B, Russ R, Horst M, Floyd J, Henson N, Hawkins K, Groom J, Parikh A, Blake L, Bland L, Thompson A, Kirincich A, Moreau C, Hudson J, Bowyer Fr, Lin T and Black AJ, Adult reserve stem cells and their potential for tissue engineering. Cell Biochem Biophys 40:1-80 (2004).
37. Caplan A, Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213:341-347 (2007).
38. Underhill GH, Galie P, Chen CS and Bhatia SN, Bioengineering methods for analysis of cells in vitro. Annu Rev Cell Dev Biol 28:385-410 (2012).
39. Peters A and Brey D, High-throughput and combinatorial technologies for tissue engineering applications. Tissue Eng Part B Rev 15:225-239 (2009).
40. Xia Y and Whitesides GM, Soft lithography. Annu Rev Mat Sci 28:153-184 (1998).
41. Wheeldon I, Fernandez J, Bae H, Kaji H and Khademhosseini A, Biomaterials for tissue engineering, in Biomaterials for Tissue Engineering Applications: A Review of the Past and Future Trends, ed by Burdick JA and Mauck RL. Springer, New York (2011).
42. Khademhosseini A, Langer R, Borenstein J and Vacanti J, Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci 108:2480-2487 (2006).
43. Anderson DG, Putnam D, Lavik EB, Mahmood TA and Langer R, Biomaterial microarrays: rapid, microscale screening of polymer-cell interaction. Biomaterials 26:4892-4897 (2005).
44. Flaim CJ, Chien S and Bhatia SN, An extracellular matrix microarray for probing cellular differentiation. Nat Methods 2:119-125 (2005).
45. Gepp M, Ehrhart F, Shirley S, Howitz S and Zimmermann H, Dispensing of very low volumes of ultra high viscosity alginate gels:a new tool for encapsulation of adherent cells and rapid prototyping of scaffolds and implants. BioTechniques 46:31 (2009).
46. Fernandes TG, Kwon SJ, Bale SS, Lee MY, Diogo MM, Clark DS, Cabral JMS and Dordick JS, Three-dimensional cell culture microarray for high-throughput studies of stem cell fate. Biotechnol Bioeng 106:106-118 (2010).
47. Pataky K, Braschler T, Negro A, Renaud P, Lutolf M and Brugger J, Microdrop printing of hydrogel bioinks into 3D tissue-like geometries. Adv Mater 24:391-396 (2011).
48. Krause D and Scadden D, Deconstructing the complexity of a microenvironmental niche. Cell 149:16-17 (2012).
49. Li W, Jiang K and Ding S, Concise review: a chemical approach to control cell fate and function. Stem cells 30:61-68 (2012).
50. Brey D, Motlekar N, Diamond S, Mauck R, Garino J and Burdick J, High-throughput screening of a small molecule library for promoters and inhibitors of mesenchymal stem cell osteogenic differentiation. Biotechnol Bioeng 108:163-174 (2011).
51. Firestone A and Chen J, Controlling destiny through chemistry: small-molecule regulators of cell fate. ACS Chem Biol 5:15-34 (2010).
52. Ma'ayan A, Blitzer RD and Iyengar R, Toward predictive models of mammalian cells. Annu Rev Biophys Biomol Struct 34:319-349 (2005).
53. Peltier J and Schaffer DV, Systems biology approaches to understanding stem cell fate choice. IET Syst Biol 4:1-11 (2010).
54. Barbosa HS, Fernandes TG, Dias TP, Diogo MM and Cabral JM, New insights into the mechanisms of embryonic stem cell self-renewal under hypoxia: a multifactorial analysis approach. PLoS One 7:e38963 (2012).
55. Brandenberger R, Burger S, Campbell A, Fong T, Lapinskas E and Rowley JA, Cell therapy bioprocessing. BioProcess Int 9:S30-S37 (2011).
56. Wognum AW, Eaves AC and Thomas TE, Identification and isolation of hematopoietic stem cells. Arch Med Res 34:461-475 (2003).
57. Takahashi K and Yamanaka S, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676 (2006).
58. Pittenger MF, Mesenchymal stem cells from adult bone marrow. Methods Mol Biol 449:27-44 (2008).
59. Rodrigues CA, Fernandes TG, Diogo MM, da Silva CL and Cabral JM, Stem cell cultivation in bioreactors. Biotechnol Adv 29:815-829 (2011).
60. Kehoe DE, Jing D, Lock LT and Tzanakakis EM, Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. Tissue Eng Part A 16:405-421 (2010).
61. Singh V, Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology 30:149-158 (1999).
62. Azarin SM and Palecek SP, Development of scalable culture systems for human embryonic stem cells. Biochem Eng J 48:378 (2010).
63. King JA and Miller WM, Bioreactor development for stem cell expansion and controlled differentiation. Curr Opin Chem Biol 11:394-398 (2007).
64. Dos Santos FF, Andrade PZ, da Silva CL and Cabral JM, Bioreactor design for clinical-grade expansion of stem cells. Biotechnol J 8:644-654 (2013).
65. Rodrigues CA, Diogo MM, da Silva CL and Cabral JM, Microcarrier expansion of mouse embryonic stem cell-derived neural stem cells in stirred bioreactors. Biotechnol Appl Biochem 58:231-242 (2011).
66. Fernandes AM, Fernandes TG, Diogo MM, da Silva CL, Henrique D and Cabral JM, Mouse embryonic stem cell expansion in a microcarrier-based stirred culture system. J Biotechnol 132:227-236 (2007).
67. Fernandes-Platzgummer A, Diogo MM, Baptista RP, da Silva CL and Cabral JM, Scale-up of mouse embryonic stem cell expansion in stirred bioreactors. Biotechnol Prog 27:1421-1432 (2011).
68. Shafa M, Sjonnesen K, Yamashita A, Liu S, Michalak M, Kallos MS and Rancourt DE, Expansion and long-term maintenance of induced pluripotent stem cells in stirred suspension bioreactors. J Tissue Eng Regen Med 6:462-472 (2012).
69. Rafiq QA, Brosnan KM, Coopman K, Nienow AW and Hewitt CJ, Culture of human mesenchymal stem cells on microcarriers in a 5 L stirred-tank bioreactor. Biotechnol Lett 35:1233-1245 (2013).
70. Timmins NE, Kiel M, Gunther M, Heazlewood C, Doran MR, Brooke G and Atkinson K, Closed system isolation and scalable expansion of human placental mesenchymal stem cells. Biotechnol Bioeng 109:1817-1826 (2012).
71. Chen AK, Reuveny S and Oh SK, Application of human mesenchymal and pluripotent stem cell microcarrier cultures in cellular therapy: achievements and future direction. Biotechnol Adv:(Ahead of print) doi:10.1016/j.biotechadv.2013.1003.1006. (2013).
72. Santos F, Andrade PZ, Abecasis MM, Gimble JM, Chase LG, Campbell AM, Boucher S, Vemuri MC, Silva CL and Cabral JM, Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. Tissue Eng Part C Methods 17:1201-1210 (2011).
73. Chen AK, Chen X, Choo AB, Reuveny S and Oh SK, Critical microcarrier properties affecting the expansion of undifferentiated human embryonic stem cells. Stem Cell Res 7:97-111 (2011).
74. Nie Y, Bergendahl V, Hei DJ, Jones JM and Palecek SP, Scalable culture and cryopreservation of human embryonic stem cells on microcarriers. Biotechnol Prog 25:20-31 (2009).
75. Bardy J, Chen AK, Lim YM, Wu S, Wei S, Weiping H, Chan K, Reuveny S and Oh SK, Microcarrier suspension cultures for high-density expansion and differentiation of human pluripotent stem cells to neural progenitor cells. Tissue Eng Part C Methods 19:166-180 (2013).
76. Serra M, Brito C, Sousa MF, Jensen J, Tostoes R, Clemente J, Strehl R, Hyllner J, Carrondo MJ and Alves PM, Improving expansion of pluripotent human embryonic stem cells in perfused bioreactors through oxygen control. J Biotechnol 148:208-215 (2010).
77. Lecina M, Ting S, Choo A, Reuveny S and Oh S, Scalable platform for human embryonic stem cell differentiation to cardiomyocytes in suspended microcarrier cultures. Tissue Eng Part C Methods 16:1609-1619 (2010).
78. Lock LT and Tzanakakis ES, Expansion and differentiation of human embryonic stem cells to endoderm progeny in a microcarrier stirred-suspension culture. Tissue Eng Part A 15:2051-2063 (2009).
79. Yuan Y, Kallos MS, Hunter C and Sen A, Improved expansion of human bone marrow-derived mesenchymal stem cells in microcarrier-based suspension culture. J Tissue Eng Regen Med: (ahead of print) doi:10.1002/term.1515. (2012).
80. Melkoumian Z, Weber JL, Weber DM, Fadeev AG, Zhou Y, Dolley-Sonneville P, Yang J, Qiu L, Priest CA, Shogbon C, Martin AW, Nelson J, West P, Beltzer JP, Pal S and Brandenberger R, Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nat Biotechnol 28:606-610 (2010).
81. Bartosh TJ, Ylostalo JH, Mohammadipoor A, Bazhanov N, Coble K, Claypool K, Lee RH, Choi H and Prockop DJ, Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Nat Acad Sci USA 107:13724-13729 (2010).
82. Baraniak PR and McDevitt TC, Scaffold-free culture of mesenchymal stem cell spheroids in suspension preserves multilineage potential. Cell Tissue Res 347:701-711 (2012).
83. Frith JE, Thomson B and Genever PG, Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential. Tissue Eng Part C Methods 16:735-749 (2010).
84. Amit M, Laevsky I, Miropolsky Y, Shariki K, Peri M and Itskovitz-Eldor J, Dynamic suspension culture for scalable expansion of undifferentiated human pluripotent stem cells. Nat Protoc 6:572-579 (2011).
85. O'Brien C and Laslett AL, Suspended in culture-human pluripotent cells for scalable technologies. Stem Cell Res 9:167-170 (2012).
86. Zweigerdt R, Olmer R, Singh H, Haverich A and Martin U, Scalable expansion of human pluripotent stem cells in suspension culture. Nat Protoc 6:689-700 (2011).
87. Olmer R, Lange A, Selzer S, Kasper C, Haverich A, Martin U and Zweigerdt R, Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Eng Part C Methods 18:772-784 (2012).
88. Chen VC, Couture SM, Ye J, Lin Z, Hua G, Huang HI, Wu J, Hsu D, Carpenter MK and Couture LA, Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res 8:388-402 (2012).
89. Ungrin MD, Clarke G, Yin T, Niebrugge S, Nostro MC, Sarangi F, Wood G, Keller G and Zandstra PW, Rational bioprocess design for human pluripotent stem cell expansion and endoderm differentiation based on cellular dynamics. Biotechnol Bioeng 109:853-866 (2012).
90. Ungrin MD, Joshi C, Nica A, Bauwens C and Zandstra PW, Reproducible, ultra high-throughput formation of multicellular organization from single cell suspension-derived human embryonic stem cell aggregates. PloS one 3:e1565 (2008).
91. Steiner D, Khaner H, Cohen M, Even-Ram S, Gil Y, Itsykson P, Turetsky T, Idelson M, Aizenman E, Ram R, Berman-Zaken Y and Reubinoff B, Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension. Nat Biotechnol 28:361-364 (2010).
92. Narkilahti S, Rajala K, Pihlajamaki H, Suuronen R, Hovatta O and Skottman H, Monitoring and analysis of dynamic growth of human embryonic stem cells: comparison of automated instrumentation and conventional culturing methods. Biomed Eng Online 6:11 (2007).
93. Thomas RJ, Chandra A, Liu Y, Hourd PC, Conway PP and Williams DJ, Manufacture of a human mesenchymal stem cell population using an automated cell culture platform. Cytotechnology 55:31-39 (2007).
94. Thomas RJ, Hourd PC and Williams DJ, Application of process quality engineering techniques to improve the understanding of the in vitro processing of stem cells for therapeutic use. J Biotechnol 136:148-155 (2008).
95. Haupt S, Grutzner J, Thier MC, Kallweit T, Rath BH, Laufenberg I, Forgber M, Eberhardt J, Edenhofer F and Brustle O, Automated selection and harvesting of pluripotent stem cell colonies. Biotechnol Appl Biochem 59:77-87 (2012).
96. Terstegge S, Laufenberg I, Pochert J, Schenk S, Itskovitz-Eldor J, Endl E and Brustle O, Automated maintenance of embryonic stem cell cultures. Biotechnol Bioeng 96:195-201 (2007).
97. Thomas RJ, Anderson D, Chandra A, Smith NM, Young LE, Williams D and Denning C, Automated, scalable culture of human embryonic stem cells in feeder-free conditions. Biotechnol Bioeng 102:1636-1644 (2009).
98. McLaren D, Gorba T, Marguerie de Rotrou A, Pillai G, Chappell C, Stacey A, Lingard S, Falk A, Smith A, Koch P, Brustle O, Vickers R, Tinsley J, Flanders D, Bello P and Craig S, Automated large-scale culture and medium-throughput chemical screen for modulators of proliferation and viability of human induced pluripotent stem cell-derived neuroepithelial-like stem cells. J Biomol Screen 18:258-268 (2013).
99. Ratcliffe E, Glen KE, Workman VL, Stacey AJ and Thomas RJ, A novel automated bioreactor for scalable process optimisation of haematopoietic stem cell culture. J Biotechnol 161:387-390 (2012).
100. Diogo MM, da Silva CL and Cabral JM, Separation technologies for stem cell bioprocessing. Biotechnol Bioeng 109:2699-2709 (2012).
101. Weissman IL and Shizuru JA, The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 112:3543-3553 (2008).
102. González-González M, Vázquez-Villegas P, García-Salinas C and Rito-Palomares M, Current strategies and challenges for the purification of stem cells. J Chem Technol Biot 87:2-10 (2012).
103. Fong CY, Peh GS, Gauthaman K and Bongso A, Separation of SSEA-4 and TRA-1-60 labelled undifferentiated human embryonic stem cells from a heterogeneous cell population using magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS). Stem Cell Rev 5:72-80 (2009).
104. Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R and Isacson O, Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 25:2257-2268 (2007).
105. Reddy LH, Arias JL, Nicolas J and Couvreur P, Magnetic nanoparticles:design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev 112:5818-5878 (2012).
106. Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S and Yamashita JK, Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One 6:e23657 (2011).
107. Schriebl K, Lim S, Choo A, Tscheliessnig A and Jungbauer A, Stem cell separation: a bottleneck in stem cell therapy. Biotechnol J 5:50-61 (2010).
108. Terstegge S, Winter F, Rath BH, Laufenberg I, Schwarz C, Leinhaas A, Levold F, Dolf A, Haupt S, Koch P, Endl E and Brustle O, Laser-assisted photoablation of human pluripotent stem cells from differentiating cultures. Stem Cell Rev 6:260-269 (2010).
109. Kumar A and Srivastava A, Cell separation using cryogel-based affinity chromatography. Nat Protoc 5:1737-1747 (2010).
110. Cabral JM, Cell partitioning in aqueous two-phase polymer systems. Adv Biochem Eng Biotechnol 106:151-171 (2007).
111. Kumar A, Kamihira M, Galaev IY, Mattiasson B and Iijima S, Type-specific separation of animal cells in aqueous two-phase systems using antibody conjugates with temperature-sensitive polymers. Biotechnol Bioeng 75:570-580 (2001).
112. Sousa AF, Andrade PZ, Pirzgalska RM, Galhoz TM, Azevedo AM, da Silva CL, Aires-Barros MR and Cabral JM, A novel method for human hematopoietic stem/progenitor cell isolation from umbilical cord blood based on immunoaffinity aqueous two-phase partitioning. Biotechnol Lett 33:2373-2377 (2011).
113. Gonzalez-Gonzalez M and Rito-Palomares M, Aqueous two-phase systems strategies to establish novel bioprocesses for stem cells recovery. Crit Rev Biotechnol (ahead of print) doi:10.3109/07388551.2013.794125 (2013).
114. Tang C, Lee AS, Volkmer JP, Sahoo D, Nag D, Mosley AR, Inlay MA, Ardehali R, Chavez SL, Pera RR, Behr B, Wu JC, Weissman IL and Drukker M, An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 29:829-834 (2011).
115. Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP, Vidal JG, Mu Y, Killian RL, Israel MA, Emre N, Marsala S, Marsala M, Gage FH, Goldstein LS and Carson CT, Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One 6:e17540 (2011).
116. Despres D, Flohr T, Uppenkamp M, Baldus M, Hoffmann M, Huber C and Derigs HG, CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device. J Hematoth Stem Cell 9:557-564 (2000).
117. Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA and O'Reilly RJ, Characteristics of CliniMACS(R) System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia - Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Tr 18:690-697 (2012).
118. Aktas M, Radke TF, Strauer BE, Wernet P and Kogler G, Separation of adult bone marrow mononuclear cells using the automated closed separation system Sepax. Cytotherapy 10:203-211 (2008).
119. Nery AA, Wrenger C and Ulrich H, Recognition of biomarkers and cell-specific molecular signatures: aptamers as capture agents. J Sep Sci 32:1523-1530 (2009).
120. Radom F, Jurek PM, Mazurek MP, Otlewski J and Jelen F, Aptamers: molecules of great potential. Biotechnol Adv (ahead of print) doi:10.1016/j.biotechadv.2013.04.007 (2013).
121. Mayer G, Ahmed MS, Dolf A, Endl E, Knolle PA and Famulok M, Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat Protoc 5:1993-2004 (2010).
122. Guo KT, SchAfer R, Paul A, Gerber A, Ziemer G and Wendel HP, A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells 24:2220-2231 (2006).
123. Iwagawa T, Ohuchi SP, Watanabe S and Nakamura Y, Selection of RNA aptamers against mouse embryonic stem cells. Biochimie 94:250-257 (2012).
124. Wang XB, Yang J, Huang Y, Vykoukal J, Becker FF and Gascoyne PR, Cell separation by dielectrophoretic field-flow-fractionation. Anal Chem 72:832-839 (2000).
125. Tan HL, Fong WJ, Lee EH, Yap M and Choo A, mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 27:1792-1801 (2009).
126. Schriebl K, Satianegara G, Hwang A, Tan HL, Fong WJ, Yang HH, Jungbauer A and Choo A, Selective removal of undifferentiated human embryonic stem cells using magnetic activated cell sorting followed by a cytotoxic antibody. Tissue Eng Part A 18:899-909 (2012).
127. Ben-David U, Gan QF, Golan-Lev T, Arora P, Yanuka O, Oren YS, Leikin-Frenkel A, Graf M, Garippa R, Boehringer M, Gromo G and Benvenisty N, Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 12:167-179 (2013).
128. Singh A, Suri S, Lee T, Chilton JM, Cooke MT, Chen W, Fu J, Stice SL, Lu H, McDevitt TC and Garcia AJ, Adhesion strength-based, label-free isolation of human pluripotent stem cells. Nat Methods 10:438-444 (2013).
129. Coopman K, Large-scale compatible methods for the preservation of human embryonic stem cells: current perspectives. Biotechnol Prog 27:1511-1521 (2011).
130. Ji L, de Pablo JJ and Palecek SP, Cryopreservation of adherent human embryonic stem cells. Biotechnol Bioeng 88:299-312 (2004).
131. Heng BC, Ye CP, Liu H, Toh WS, Rufaihah AJ, Yang Z, Bay BH, Ge Z, Ouyang HW, Lee EH and Cao T, Loss of viability during freeze-thaw of intact and adherent human embryonic stem cells with conventional slow-cooling protocols is predominantly due to apoptosis rather than cellular necrosis. J Biomed Sci 13:433-445 (2006).
132. Borel Rinkes IH, Toner M, Ezzell RM, Tompkins RG and Yarmush ML, Effects of dimethyl sulfoxide on cultured rat hepatocytes in sandwich configuration. Cryobiology 29:443-453 (1992).
133. Serra M, Correia C, Malpique R, Brito C, Jensen J, Bjorquist P, Carrondo MJ and Alves PM, Microencapsulation technology:a powerful tool for integrating expansion and cryopreservation of human embryonic stem cells. PLoS One 6:e23212 (2011).
134. Ilic N, Savic S, Siegel E, Atkinson K and Tasic L, Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the US and Australia: part I-a method of manual documentary analysis. Stem Cells Transl Med 1:898-908 (2012).
135. EMA, Reflection paper on stem cell-based medicinal products - http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500101692 (2011).
136. Fink DW Jr, FDA regulation of stem cell-based products. Science 324:1662-1663 (2009).
137. Feigal EG, Tsokas K, Zhang J, Cromer MV, Whittlesey KJ and Werner MJ, Perspective: communications with the Food and Drug Administration on the development pathway for a cell-based therapy: why, what, when, and how? Stem Cells Transl Med 1:825-832 (2012).
138. Fluri DA, Tonge PD, Song H, Baptista RP, Shakiba N, Shukla S, Clarke G, Nagy A and Zandstra PW, Derivation, expansion and differentiation of induced pluripotent stem cells in continuous suspension cultures. Nat Methods 9:509-516 (2012).
139. Shafa M, Day B, Yamashita A, Meng G, Liu S, Krawetz R and Rancourt DE, Derivation of iPSCs in stirred suspension bioreactors. Nat Methods 9:465-466 (2012).
140. Zimmermann A, Preynat-Seauve O, Tiercy JM, Krause KH and Villard J, Haplotype-based banking of human pluripotent stem cells for transplantation:potential and limitations. Stem Cells Dev 21:2364-2373 (2012).
141. Cyranoski D, Stem-cell pioneer banks on future therapies. Nature 488:139 (2012).